The majority of these studies provided evidence that angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) do not adversely affect the COVID-19 progression or may even be beneficial [22,23,24,25,26,27,28]. Here, ACE is linked to COVID-19.